TRIMETAZIDINE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H22N2O3
Molecular Weight	266.3361
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

COC1=CC=C(CN2CCNCC2)C(OC)=C1OC

InChI

InChIKey=UHWVSEOVJBQKBE-UHFFFAOYSA-N

InChI=1S/C14H22N2O3/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16/h4-5,15H,6-10H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C14H22N2O3
Molecular Weight	266.3361
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Trimetazidine is a medicine, which is used for the treatment of angina pectoris. The drug mechanism of action is explained by its ability to selectively inhibit long-chain 3-ketoacyl coenzyme A thiolase, an enzyme responsible for mitochondrial beta-oxidation of long chain fatty acids. Trimetazidine also increases pyruvate dehydrogenase activity, binds to the mitochondrial membrane, directly inhibits cardiac fibrosis and improves mechanical resistance of the sarcolemma.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Trifunctional enzyme subunit beta, mitochondrial 2	Inhibitor 8,297		75.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Angina pectoris 106	Primary		Approved 8,429	VASTAREL

PubMed

Show entries

Title	Date	PubMed
The efficacy of medication on tinnitus due to acute acoustic trauma.	2001	11318462
Comments on EMIP-FR study's editorial.	2001 Aug	11465969
S15176 and S16950 interaction with Cyclosporin A antiproliferative effect on cultured human lymphocytes.	2001 Feb	11468012
Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?	2001 Feb	11286307
Anti-ischaemic efficacy and tolerability of trimetazidine administered to patients with angina pectoris: results of three studies.	2001 Feb	11286304

Showing 1 to 5 of 24 entries

Previous1 2 3 4 5Next

Patents

Sample Use Guides

In Vivo Use Guide

The dose is one tablet of 20 mg of trimetazidine three times a day or 35 mg twice a day during meals.

Route of Administration: Oral

In Vitro Use Guide

Rat cardiomyocytes were treated with trimetazidine (1-5*10(-4) M final concentration) in the bath. Then the cells were submitted either to 150 min normoxia or to 150 min hypoxia followed by 90 min reoxygenation in the absence of oxidizable substrate. The drug (at 5*10(-4) M) was efficient in protecting the isolated cardiac myocytes against the functional alterations induced by substrate-free hypoxia and led thus to a better recovery upon reoxygenation.